收费全文 | 10795篇 |
免费 | 473篇 |
国内免费 | 43篇 |
耳鼻咽喉 | 89篇 |
儿科学 | 247篇 |
妇产科学 | 206篇 |
基础医学 | 1348篇 |
口腔科学 | 304篇 |
临床医学 | 687篇 |
内科学 | 2771篇 |
皮肤病学 | 214篇 |
神经病学 | 579篇 |
特种医学 | 395篇 |
外科学 | 1991篇 |
综合类 | 29篇 |
预防医学 | 262篇 |
眼科学 | 150篇 |
药学 | 770篇 |
中国医学 | 31篇 |
肿瘤学 | 1238篇 |
2021年 | 127篇 |
2020年 | 79篇 |
2019年 | 121篇 |
2018年 | 138篇 |
2017年 | 115篇 |
2016年 | 126篇 |
2015年 | 136篇 |
2014年 | 157篇 |
2013年 | 232篇 |
2012年 | 370篇 |
2011年 | 399篇 |
2010年 | 262篇 |
2009年 | 207篇 |
2008年 | 384篇 |
2007年 | 482篇 |
2006年 | 518篇 |
2005年 | 484篇 |
2004年 | 488篇 |
2003年 | 468篇 |
2002年 | 480篇 |
2001年 | 418篇 |
2000年 | 451篇 |
1999年 | 396篇 |
1998年 | 120篇 |
1997年 | 103篇 |
1996年 | 99篇 |
1995年 | 79篇 |
1994年 | 78篇 |
1993年 | 71篇 |
1992年 | 346篇 |
1991年 | 311篇 |
1990年 | 274篇 |
1989年 | 306篇 |
1988年 | 234篇 |
1987年 | 236篇 |
1986年 | 236篇 |
1985年 | 277篇 |
1984年 | 131篇 |
1983年 | 123篇 |
1982年 | 66篇 |
1979年 | 104篇 |
1978年 | 84篇 |
1977年 | 75篇 |
1974年 | 62篇 |
1972年 | 62篇 |
1971年 | 65篇 |
1969年 | 77篇 |
1968年 | 91篇 |
1967年 | 61篇 |
1966年 | 82篇 |
Background
The Tama-REgistry of Acute endovascular Thrombectomy (TREAT) is a multicenter registry of endovascular thrombectomy in the Tama area of Tokyo. The objective of this study was to confirm the real-world status of 2 paradigms of transportation.Methods
This was a retrospective analysis of data from TREAT. Patients were divided into 2 groups and 2 periods: directly admitted to an endovascular thrombectomy-capable center (ECC; group D)/secondary transfer from a non-ECC (group S), and the first period/the second period. Transfer distance, workflow metrics, and clinical outcomes were analyzed.Results
A total of 326 patients, including 264 in group D and 62 in group S, were analyzed. The median distance from the onset-to-ECC was 3.62km for group D and 7.87km for group S (P < .001). The median onset-to-needle (OTN) time was longer for group S (168 minutes) than group D (138 minutes; P?=?.006). The median onset-to-reperfusion (OTR) time was significantly shorter for group D (247 minutes) than for group S (304 minutes; P?=?.029). With respect to the 2 periods, there was no significant difference in onset-to-puncture time between the 2 groups in the first period (207 minutes versus 243.5 minutes, respectively, P?=?.50), while there was one in the second period (164 minutes versus 246.5 minutes, respectively, P?=?.02).Conclusions
This region-wide registry study showed longer OTN and OTR times, with no improvement of the time course over time in patients transported via non-ECCs. These results should be used to create a regional medical policy for the management of acute ischemic stroke. 相似文献Hereditary transthyretin-mediated (hATTR) amyloidosis is a progressive, debilitating disease often resulting in early-onset, life-impacting autonomic dysfunction. The effect of the RNAi therapeutic, patisiran, on autonomic neuropathy manifestations in patients with hATTR amyloidosis with polyneuropathy in the phase III APOLLO study is reported. Patients received patisiran 0.3 mg/kg intravenously (n = 148) or placebo (n = 77) once every 3 weeks for 18 months. Patisiran halted or reversed polyneuropathy and improved quality of life from baseline in the majority of patients. At baseline, patients in APOLLO had notable autonomic impairment, as demonstrated by the Composite Autonomic Symptom Score-31 (COMPASS-31) questionnaire and Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) questionnaire autonomic neuropathy domain. At 18 months, patisiran improved autonomic neuropathy symptoms compared with placebo [COMPASS-31, least squares (LS) mean difference, − 7.5; 95% CI: − 11.9, − 3.2; Norfolk QOL-DN autonomic neuropathy domain, LS mean difference, − 1.1; − 1.8, − 0.5], nutritional status (modified body mass index, LS mean difference, 115.7; − 82.4, 149.0), and vasomotor function (postural blood pressure, LS mean difference, − 0.3; − 0.5, − 0.1). Patisiran treatment also led to improvement from baseline at 18 months for COMPASS-31 (LS mean change from baseline, − 5.3; 95% CI: − 7.9, − 2.7) and individual domains, orthostatic intolerance (− 4.6; − 6.3, − 2.9) and gastrointestinal symptoms (− 0.8; − 1.5, − 0.2). Rapid worsening of all study measures was observed with placebo, while patisiran treatment resulted in stable or improved scores compared with baseline. Patisiran demonstrates benefit across a range of burdensome autonomic neuropathy manifestations that deteriorate rapidly without early and continued treatment.
相似文献